Table 2. Demographics and baseline clinical characteristics (Patients with previous stroke or TIA) of included randomized controlled trials.
| Characteristics | Trial |
|||||
|---|---|---|---|---|---|---|
| RE-LY |
ROCKET AF |
ARISTOTLE | ||||
| Dabigatran 110 | Dabigatran 150 | Warfarin | Rivaroxaban | Warfarin | ||
| Total (n) | 1195 | 1233 | 1195 | 3754 | 3714 | 3436 |
| Age(years) | 70.2(9.4) | 70.8(10.1) | 70.4(9.5) | 71(64-76) | 71(64-77) | 70.1(9.5) |
| Men, % | 64.1 | 62.2 | 62.4 | 61 | 61 | 63 |
| CHADS2≥3, % | 90.0 | 90.2 | 88.6 | 92 | ||
| CHADS2 2, % | 10.0 | 9.8 | 11.4 | Median CHADS2 4(3-5) | Median CHADS2 4(3-5) | 8 |
| CHADS2 1, % | 0 | 0 | 0 | 0 | ||
| Vitamin K antagonist naïve, % | 43.9 | 44 | 45.8 | 41 | 41 | 39 |
| Diabetes,% | 22.4 | 23.7 | 21.4 | 25 | 24 | 26 |
| Hypertension,% | 77 | 77.3 | 76.2 | 85 | 85 | 83 |
Table constructed as per available data in the included trials. For RE-LY and ARISTOTLE trial, Data are mean (SD) or number (%), if not specified. For ROCKET AF trial, Data are median (IQR) or number (%), if not specified. TIA: Transient ischemic attack.